Abstract:Background Heart transplantation (HTx) is a treatment option for patients with end-stage heart failure (HF) who remain symptomatic despite optimal medical therapy. There is a growing number of patients undergoing HTx. Non-alcoholic fatty liver disease (NAFLD) is known to increase the risk of adverse outcomes. At this moment, there is limited scientific evidence of clinical outcomes in HTx patients affected by NAFLD. Therefore, we sought to investigate this population. Methods We queried NIS between 2017-2020 for adult patients who were hospitalized for HTx and had NAFLD. The primary outcome was inpatient mortality. The secondary outcomes were cardiogenic shock, cardiac arrest, gastrointestinal bleeding (GIB), invasive mechanical ventilation, length of stay (LOS) and total hospital cost. Multivariable logistic and Poisson regression analyses were used to estimate clinical outcomes. p-value < 0.05 was significant. Results There were 11,795 hospitalizations for HTx, of which 1,215 (10.3%) had NAFLD. NAFLD and non-NAFLD cohorts were with mean age of 51.0 vs. 54.3 yrs; males 74% vs 71.5%; Caucasians 61.7% vs 58.4%; HF 94.6% vs 96.2%; LVAD 14.8% vs 19.1%, obesity 11.1% vs 12.5%; HLD 22.6% vs 37.1%; anemia 10% vs 15%, DM 24.2% vs 33.2%; AF 33.3% vs 40.2%; CKD 43.2% vs 45.3%, history of MI 4.1% vs 12.6%; stroke 6.5% vs 3.7%, COPD 5.7% vs 8.9%, respectively. NAFLD subgroup experienced complications with ACS 8.6% vs 3.1%, severe sepsis 24.6% vs 5%, ARF 44% vs 22.5%. NAFLD cohort had significantly higher mortality and worse clinical outcomes (Table 1). Conclusion Patients undergoing heart transplantation with co-existent NAFLD demonstrated significantly worse clinical outcomes and higher resource utilization. They were younger and less comorbid overall. NAFLD is associated with increased rates of acute complications, GIB, cardiac and respiratory failure. Detection and appropriate management of NAFLD in patients undergoing HTx would improve clinical results. More research is needed to describe long-term outcomes.

Extrahepatic Organs in the Development of Non-Alcoholic Fatty Liver Disease in Liver Transplant Patients.

Extrahepatic organs in the development of non-alcoholic fatty liver disease in liver transplant patients

Endoscopic Bariatric and Metabolic Therapies for Liver Disease: Mechanisms, Benefits, and Associated Risks

Role of the Immune System in Liver Transplantation and Its Implications for Therapeutic Interventions

Navigating Immune Cell Immunometabolism after Liver Transplantation

Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation

Liver transplantation and nonalcoholic steatohepatitis: the state of the art

An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease

Optimizing patients with non-alcoholic fatty liver disease pre-transplant

Non-alcoholic Fatty Liver Disease and Liver Transplantation

LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease.

Higher Mortality And Resource Utilization In Patients Undergoing Cardiac Transplantation Affected By Non-alcoholic Fatty Liver Disease, Nation-Wide Study

Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease

Hepatic steatosis after liver transplantation: a systematic review and meta-analysis

The Gut Microbiome and Gut-Liver Axis in NAFLD

Metabolic Complications in Liver Transplantation Recipients: How We Can Optimize Long‐Term Survival

The Molecular and Mechanistic Insights Based on Gut–Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement